The trading price of INmune Bio Inc (NASDAQ:INMB) closed lower on Friday, January 17, and closing at $6.45, -4.02% lower than its previous close.
Traders who pay close attention to intraday price movement should know that it fluctuated between $6.035 and $6.8. In examining the 52-week price action we see that the stock hit a 52-week high of $14.74 and a 52-week low of $4.32. Over the past month, the stock has gained 26.97% in value.
INmune Bio Inc, whose market valuation is $143.01 million at the time of this writing, is expected to release its quarterly earnings report in February. Investors’ optimism about the company’s current quarter earnings report is understandable.
On the technical side, indicators suggest INMB has a Hold on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 50% Sell, while an average of long term indicators suggests that the stock is currently Hold.
A quick review shows that INMB’s price is currently 22.78% off the SMA20 and 22.90% off the SMA50. The RSI metric on the 14-day chart is currently showing 63.48, and weekly volatility stands at 13.38%. When measured over the past 30 days, the indicator reaches 9.30%. INmune Bio Inc (NASDAQ:INMB)’s beta value is currently sitting at 1.77, while the Average True Range indicator is currently displaying 0.53. With analysts defining $22-$22 as the low and high price targets, we arrive at a consensus price target of $22 for the trailing 12-month period. The current price is about -241.09% off the estimated low and -241.09% off the forecast high, based on this estimate. Investors will be thrilled if INMB’s share price rises to $22, which is the median consensus price. At that level, INMB’s share price would be -241.09% below current price.
To see how INmune Bio Inc stock has been performing in comparison to its peers in the industry, here are the numbers: INMB stock’s performance was -4.02% in the latest trading, and -43.17% in the past year.
An evaluation of the daily trading volume of INmune Bio Inc (NASDAQ:INMB) indicates that the 3-month average is 270.02K. However, this figure has increased over the past 10 days to an average of 0.51.
Currently, records show that 22.17 million of the company’s shares remain outstanding. The insiders hold 28.90% of outstanding shares, whereas institutions hold 27.21%. The stats also highlight that short interest as of 2024-12-31, stood at 4.28 million shares, resulting in a short ratio of 18.51 at that time. From this, we can conclude that short interest is 2420.00 of the company’s total outstanding shares. It is noteworthy that short shares in December were up slightly from the previous month’s figure, which was 3.71 million. However, since the stock’s price has seen 38.12% year-to-date, investors’ interest is likely to be reignited due to its potential to move even higher.
